Cellares closed a $257 million Series D to expand its automated cell‑therapy manufacturing services and move toward commercial operations in advance of a planned 2027 IPO. The company plans to scale its robotic manufacturing platform to support CAR‑T and other ex vivo cell therapies for multiple customers. The financing underscores investor demand for CDMO solutions that address the high cost and technical complexity of cell therapy manufacturing. Cellares aims to convert capital into deployed manufacturing capacity and commercial contracts; success will hinge on client adoption, regulatory-compliant operations and the ability to reduce per‑dose costs through automation.